Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifty-two cases of giant cell tumor of bone have been treated by cryosurgery--an extensive freezing of residual tumor after curettage. Cryosurgery is performed by direct pouring of liquid nitrogen into the tumor cavity through a funnel. The cavity is filled with methylmethacrylate and corticocancellous onlay grafts until peripheral bone regeneration occurs to provide bone stability and prevent postoperative pathologic fracture. Patients with lesions in a weight bearing bone are placed in a long leg ischial weight bearing brace until sufficient healing has taken place. Rebiopsy (a second stage diagnostic procedure) is performed 3-6 months after the original cryosurgery. By comparison of pathology, results and complications between our first series of 25 cases and the additional 27, we have observed only one frank malignant giant cell tumor (1.9% incidence). This is much lower than the previously reported 16% fully malignant complication rate, and may be the result of the rapid elimination of the giant cell tumor by cryosurgery.
 ...
PMID:Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases. 72 55

The experience with proved pancreatic adenocarcinoma in Portland, Ore, for 1965 through 1975 is compared with the decade 1955 through 1965. Little difference is found in time of diagnosis, incidence of resection vs bypass or laparotomy, types of resection, and overall survival. However, operative mortality improved and survival after total pancreatectomy improved from seven to 23 months. Whipple resections leave residual pancreatic tumor in one third of patients. Combining fluorouracil and radiotherapy significantly increases survival after palliative bypass (15 months vs 7.4 months, P less than .02). Based on low operative mortality, improved survival, and avoidance or residual tumor, use of total pancreatectomy as the resection of choice is recommended.
 ...
PMID:Adenocarcinoma of the pancreas. A ten-year experience. 73 71

In order to avoid post-operative cosmetic and functional disabilities, we introduced simultaneous surgery, radiotherapy and regional chemotherapy in treating carcinomas of the maxillary sinus in October 1964 and have been working to perfect this procedure ever since. This combined therapy consists of 1) a "reduction operation," i.e., reduction of the tumor mass, succeeded by daily cleaning of the residual tumor, 2) six external irradiation (mean dose is 1,200 rads/over a period of nine days) treatments and 3) five intra-arterial infusions of 5-fluorouracil (5-FU) (250 mg daily) and broxuridine (BUdR) (500 mg daily). The degenerative changes of the tumor cells, as observed by histopathological examinations, appear so rapidly that, when six irradiation treatments and five infusions were given, 80% of the cases showed marked irreversible change. This degeneration is not affected by the degree of differentiation. In other words, no variation was observed between well and poorly differentiated squamous cell carcinomas. In 77 cases infused with 5-FU alone, the five-year survival rate was 55%. Seventy-six percent of 45 cases infused with BUdR as well as 5-FU were still living after five years. We want to emphasize that these survivors are able to return to normal life with their eyes and palates well rehabilitated.
 ...
PMID:Combined surgery, radiotherapy and regional chemotherapy in carcinoma of the maxillary sinus. 75 9

In order to elucidate the effect of surgical removal of the regional nodes on the immunological defence of the host against the tumor, as well as on the cure rate of C3H/He mice transplanted with MH 134, three separate experiments were carried out, and the following results were obtained: 1) The cure rates of mice treated by removal of the primary tumor with regional lymph nodes were significantly lower than that of mice treated by simple amputation without regional lymphadenectomy. 2) It was demonstrated by a bioassay of the regional node that viable tumor cells presented in the nodes prior to the operation disappeared after removal of the primary tumor, whereas in 60-Co irradiated mice prior to the tumor inoculation, such phenomena were not observed. 3) Observation utilizing in vivo neutralization revealed that regional lymph node cells were capable of interfering with growth of tumor cells. These findings suggest that removal of the regional nodes impairs the restraint to the growth of residual tumor after the removal of the primary tumor, and this is probably due to a derangment of the immunologic response of the host.
 ...
PMID:Regional lymphadenectomy and tumor curability in C3H/He mice transplanted with MH 134. 76 Feb 60

A randomized study was conducted to determine the effect of cyclophosphamide on the rate of recurrence and metastases in children with localized and regional neuroblastoma. One hundred and thirty-four patients were entered and 113 were suitable for analysis. All patients had surgical resection of the primary tumor when possible, postoperative irradiation to the tumor bed when indicated for gross residual disease, and 49/113 received cyclophosphamide, 10 mg/kg/day orally for 7-10 days every 28 days for 1 year. A difference was found in the rate of metastases between the patients who did and did not receive chemotherapy; the overall survival of about 80% in both groups was better than anticipated. All relapses occurred during the first year; there were none in 27 Stage I patients, 8/52 in Stage II and 13/34 in Stage III. Toxicity was minimal, with only two patients developing hemorrhagic cystitis that prevented continued therapy.
 ...
PMID:Cyclophoshamide treatment of patients with localized and regional neuroblastoma: A randomized study. 78 89

In two large controlled cooperative trials, 1118 patients undergoing surgical resection for large bowel cancer were randomized to be treated by surgery alone or to receive 5-fluorouracil during postoperative followup. The two studies differed slightly in the selection of patients for entry and in the dose regimens of 5-fluorouracil. Following examination of the removed specimen, "curative" and palliative stratifications based on evidence of residual disease were made, so that the two trials actually consisted of five separate patient groups, two groups of patients who had "curative" resections and the other three smaller groups of patients who had palliative resections with residual disease or tumor at a margin of the resected specimen. In all five groups, survival was slightly better in patients receiving chemotherapy although no single difference is statistically significant. Any suggestion that these slight advantages represent a true therapeutic 5-FU effect must be tempered by previous negative adjuvant studies by this group as well as others. Currently the group is conducting a trial using a combination of methyl-CCNU and 5-fluorouracil and has recently added a nonspecific immunostimulant, methanol extraction residue of BCG (MER), to one subgroup.
 ...
PMID:Adjuvant chemotherapy in the surgical treatment of large bowel cancer. 79 71

In 1958, a co-operative clinical trial, involving 23 institutions, was begun to evaluate the efficacy of a short course of triethylenethiophosphoramide as an adjuvant to radical mastectomy in the treatment of patients with primary carcinoma of the breast. Of 826 women prospectively randomized so that they received either a placebo or triethylenethiophosphoramide, 99.3 per cent were available for five years of follow-up study, and 95.3 per cent have been observed for ten or more years. Results have indicated the inadequacy of standard operative therapy in effecting a permanent tumor-free state in a majority of patients. Particularly distressing was the finding that 76 per cent of all patients with positive axillary nodes--65 per cent with one to three and 86 per cent of those with more than or equal to four positive--demonstrated a treatment failure by ten years and that only 24.9 per cent survived. The survival rate of those with one to three positive nodes was 37.5 per cent and only 13.4 per cent if more than or equal to four nodes contained tumor. Also disturbing was the observation that one of four patients with negative axillary nodes displayed a treatment failure by ten years. Such findings mandate the urgency for immediate evaluation of available systemic therapeutic agents postoperatively. That systemic chemotherapy can enhance the disease-free state as well as survival rate of at least some patients with carcinoma of the breast is supported by the finding that the original observation at 18 months indicating an advantage for premenopausal women with more than or equal to four positive nodes who received triethylenethiophosphoramide persisted for as long as ten years. At that time, 21 per cent fewer patients in the triethylenethiophosphoramide group had treatment failures and 21 per cent more survived, an indication that the initial delay in treatment failure was reflected in patient survival rate. Data suggesting that the limited chemotherapy used was more effective in patients having smaller tumors are in keeping with the concept that adjuvant therapy is likely to be most effective in a host with minimal residual tumor burden. Of importance was the observation that 80 per cent of treatment failures occurring in ten years were apparent by five years of observation. Strikingly, 86 per cent of ten year treatment failures in patients with positive nodes occurred by five years. In patients with more than or equal to four positive nodes, this was so in 92 per cent of the instances. Such findings tend to discredit the claim that the worth of an alternative treatment for carcinoma of the breast can be ascertained only by a period of observation much longer than five years.
 ...
PMID:Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. 80 75

Multiple drugs, a single drug, and irradiation were compared in patients with Stage III ovarian carcinoma. The results were categorized as "favorable" [pelvic mass less than 8 cm and/or upper abdominal tumor nodule(s) less than 2 cm] or "unfavorable" (more massive disease). A total of 62 patients are reviewed of whom 25 had irradiation and 37 had chemotherapy. It was found that patients with slight residual disease after celiotomy did equally well with either irradiation or chemotherapy, but survival was improved using a combination of both. Use of 5 drugs did not significantly improve survival beyond that obtained with a single drug.
 ...
PMID:Stage III ovarian carcinoma: treatment and results. Comparison of multiple drugs, a single drug, and irradiation. 83 97

Four consecutive patients with measurable recurrent squamous cell carcinoma of the vulva were treated with Adriamycin, in small doses approximately 45 mg/square meter of body surface area every 3 weeks. Three patients achieved objective regression of nodal metastases and residual tumor with clinical subjective benefit. Tumor control was maintained for 32, 31+, and 28+ weeks.
 ...
PMID:Adriamycin treatment of advanced vulvar carcinoma. 87 32

366 patients with squamous-cell carcinoma of the oropharynx treated by external irradiation were studied to see whether residual disease at the end of treatment influences control. The frequency of recurrence was found to be significantly greater when residual disease was present. When the total dose was determined by the degree of regression of the primary lesion during treatment rather than the initial tumor volume, recurrence was significantly more frequent. Forcing the dose beyond a level suitable for the original volume of disease failed to prevent recurrence in patients with residual disease, most likely due to the hypoxic state of the remaining tumor cells.
 ...
PMID:The significance of residual disease after external irradiation of squamous-cell carcinoma of the oropharynx. 87 90


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>